New Pharma Business Opportunities in Germany

After the success of previously unknown biopharma company BioNTech in combatting Covid, Germany is back in the spotlight as “the world’s pharmacy.” But what comes next for the sector? And how can international health-sector companies profit? We talk to the world’s oldest pharmaceutical company Merck, a serial entrepreneur and a biotech journalist about personal medication, international partnerships and mRNA technology and its potential for fighting cancer.

Our guests 

Laura Matz is the Chief Science and Technology Officer for Merck, Darmstadt, Germany. An executive vice-president, she’s responsible for the corporate innovation teams including the digital office and new digital business models. She has 20 years of experience in semiconductor manufacturing and a decade of experience running semiconductor materials businesses. She has a PhD in analytical chemistry from Washington State University.

Maike Becker-Krüger studied International Relations at Lake Forest College in Chicago and at Franklin University in Switzerland. This was followed by an MBA from Quadriga University Berlin. She worked directly for state premier of the regional German state of Hessen before taking responsibility for European policy coordination within the national government. Starting in 2015, she has built up the capital city office and the Corporate and Government Relations Berlin department at Merck. Since 2022, Maike Becker-Krüger has been Head of EU & Germany Corporate Affairs.

Oliver Schacht is a corporate finance professional and expert in the molecular diagnostics industry and CEO of OpGen. He has co-founded several start-up companies in biotech, clean tech, IT and education in Europe and the US and has experience in developing and implementing commercial strategies and financing measures (including two IPOs). He also serves as the chairman of the Board of Internal Council of Biotechnology Assocations and the president of the German industry association BIO Deutschland. He studied European Business Administration in Reutlingen and London and holds a PhD from Cambridge University (UK).

Dr. Georg Kääb studied biology in Regensburg and Munich and earned his doctorate in neuroimmunology. After freelancing for the Süddeutsche Zeitung newspaper, he became editor-in-chief and co-managing director at the Association of German Biologists. From 2007 to 2021, he headed the communication of the cluster organization BioM (Martinsried), was managing director of the Biotechnology Cluster Bavaria and spokesperson for BioRegions in Germany. Since autumn 2021, he has headed the editorial team of the biotechnology magazine division at media company BIOCOM AG.

Send your feedback and comments to andreas.bilfinger@gtai.com.